Fitusiran progress should have 'significant financial effect' on Silence, company claims
US RNAi therapeutics company Alnylam Pharmaceuticals (Nasdaq: ALNY) last week announced that, along with Sanofi Genzyme, it was starting a Phase III program investigating the use of fitusiran in patients with hemophilia A and B with or without inhibitors.
This is a milestone not only for Alnylam and the biotech unit of French pharma major Sanofi (Euronext: SAN), but also for Silence Therapeutics (AIM:SLN), UK novel RNA therapeutics specialist, according to the company itself.
Silence last week referenced fitusiran within a list of Alnylam products that are being included within a claim issued in the UK courts relating to the company’s entitlement to supplementary protection certificates that extend European patent protection on those products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze